Kiora Pharmaceuticals (KPRX) Stock Price, News, Quotes-Moomoo

$Kiora Pharmaceuticals (KPRX.US)$
Kiora Pharmaceuticals (NASDAQ: KPRX)reported Q3 2024 financial results and pipeline updates. The company received approval for ABACUS-2, a Phase 2 study of KIO-301 for retinitis pigmentosa, and finalized the Phase 2 KLARITY trial design for KIO-104. Financial position remains strong with $29.0 million in cash and equivalents, plus $1.8 million in collaboration receivables from Théa partnership. Q3 net loss was $3.4 million, improved from $5.8 million in Q3...

Trytosaveabit

Oct 29 06:03

News

$Kiora Pharmaceuticals (KPRX.US)$ Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Stock_Drift

Oct 28 10:05

Low Floats. 11:03am 10/28

$CCSC Technology International (CCTG.US)$ $Ascent Solar Technologies (ASTI.US)$ $China SXT Pharmaceuticals (SXTC.US)$ $Prestige Wealth (PWM.US)$ $Kiora Pharmaceuticals (KPRX.US)$ $Wang & Lee Group (WLGS.US)$ $Avalon GloboCare (ALBT.US)$ $Safe Pro Group (SPAI.US)$ $Safe & Green Development (SGD.US)$ $AgEagle Aerial Systems (UAVS.US)$ $Top Wealth Group Holding (TWG.US)$ $Greenlane (GNLN.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊

Trytosaveabit

Sep 11 06:49

New form 4!

$Kiora Pharmaceuticals (KPRX.US)$ 4: Statement of changes in beneficial ownership of securities-Director Shapiro Aron bought 3K shares at 3.60 PS
SEC· 41 mins ago

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

KPRX Kiora Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target